Doulberis Michael, Kotronis Georgios, Gialamprinou Dimitra, Kountouras Jannis, Katsinelos Panagiotis
Bürgerspital Hospital, Department of Internal Medicine, Solothurn 4500, Switzerland.
Agios Pavlos Hospital, Department of Internal Medicine, Thessaloniki, Macedonia, 55134, Greece.
Metabolism. 2017 Jun;71:182-197. doi: 10.1016/j.metabol.2017.03.013. Epub 2017 Mar 31.
Non-alcoholic fatty liver disease (NAFLD) is a significant global health burden in children, adolescents and adults with substantial rise in prevalence over the last decades. Accumulating data from manifold studies support the idea of NAFLD as a hepatic manifestation of metabolic syndrome, being rather a systemic metabolic disease than a liver confined pathology. Emerging data support that the gut microbiome represents a significant environmental factor contributing to NAFLD development and progression. Apart from other regimens, probiotics may have a positive role in the management of NAFLD through a plethora of possible mechanisms. The current review focuses on the NAFLD multifactorial pathogenesis, including mainly the role of intestinal microbiome and all relevant issues are raised. Furthermore, the clinical manifestations and appropriate diagnostic approach of the disease are discussed, with all possible therapeutic measures that can be taken, also including the potential beneficial effect of probiotics.
非酒精性脂肪性肝病（NAFLD）是儿童、青少年和成人中一项重大的全球健康负担，在过去几十年中患病率大幅上升。来自众多研究的越来越多的数据支持了NAFLD是代谢综合征的肝脏表现这一观点，它更像是一种全身性代谢疾病而非局限于肝脏的病理学问题。新出现的数据表明，肠道微生物群是导致NAFLD发生和发展的一个重要环境因素。除其他疗法外，益生菌可能通过多种可能的机制在NAFLD的管理中发挥积极作用。本综述重点关注NAFLD的多因素发病机制，主要包括肠道微生物群的作用，并提出了所有相关问题。此外，还讨论了该疾病的临床表现和适当的诊断方法，以及可以采取的所有可能的治疗措施，其中也包括益生菌的潜在有益作用。
